The GLC Initiative helps countries gain access to high-quality second-line anti-TB drugs so they can provide treatment for people with multidrug-resistant tuberculosis (MDR-TB) in line with the WHO guidelines, the latest scientific evidence and country experiences. The Initiative consists of a secretariat, the Green Light Committee (an expert review and WHO advisory body) and the Global Drug Facility (the drug procurement arm of the Initiative).
![GLC flyer [pdf 910kb]](/entity/tb/challenges/mdr/greenlightcommittee/flyer_60px.gif)
![Instructions for applying to the Green Light Committee for access to second-line anti-tuberculosis drugs [pdf 931kb]](/entity/tb/challenges/mdr/greenlightcommittee/glcinstructionscover60px.gif)
